One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Adult 450 mg tablet source. No pediatric solution or institutional HD regimen is inferred.
The VALCYTE label provides no adult tablet dose for hemodialysis and says those tablets should not be used. UCSF lists institutional oral treatment and prophylaxis schedules in intermittent HD. This is a real label-versus-institution difference, not two independently agreeing labels.
What to reconcile: Confirm CMV indication, transplant context, formulation, dialysis schedule, cytopenias and infectious-disease input. The institutional regimen is not labeled approval; IV ganciclovir is preferred by UCSF for initiation in unstable renal function or dialysis.
Open this note and its source referencesUCSF lists prophylaxis every 48 hours during continuous HD. The Jarrell primary abstract studied daily enteral dosing in ten ICU transplant recipients on CVVHD and found that most reached a proposed trough target. These sources differ, but the study is not a comparative clinical-outcomes trial.
What to reconcile: Reconcile the actual dialysis modality and clearance, absorption, CMV risk, counts and monitoring. Full-text flow-rate details were not reviewed; no universal CRRT dose is derived or automatically preferred.
Open this note and its source referencesExactly 60 is unassigned. Institutional HD regimens differ from U.S. tablet-label limitations. IV ganciclovir is preferred at initiation with unstable renal function or dialysis. Give oral doses with food.
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >60 | 900 mg every 12 hours |
| 40-59 | 450 mg every 12 hours |
| 25-39 | 450 mg daily |
| 10-24 | 450 mg every other day |
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| >60 | 900 mg daily |
| 40-59 | 450 mg daily |
| 25-39 | 450 mg every other day |
| 10-24 | 450 mg twice weekly |
| Dialysis setting / indication | Source-specific schedule |
|---|---|
| IHD treatment | 450 mg initially, then after HD |
| IHD prevention | 450 mg twice weekly |
| Continuous HD treatment | 450 mg daily |
| Continuous HD prevention | 450 mg every other day |
Adult CrCl bands: >60 / 40-59 / 25-39 / 10-24 mL/min; exactly 60 is not assigned by the displayed webpage. CMV treatment: 900 mg orally every 12 hours / 450 mg every 12 hours / 450 mg daily / 450 mg every other day. Prevention: 900 mg daily / 450 mg daily / 450 mg every other day / 450 mg twice weekly.
Intermittent HD treatment: 450 mg initially, then after HD. HD prevention: 450 mg twice weekly. Continuous-HD treatment: 450 mg daily; prevention: 450 mg every other day. These institutional HD regimens are distinct from U.S. tablet-label limitations. IV ganciclovir is preferred when starting therapy in unstable renal function or dialysis. Give oral doses with food.
RDM30-026-valganciclovir-1 · Source locator: UCSF - valganciclovir: treatment, prevention and dialysis; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=valganciclovir&s1=RDM30-026-valganciclovir&h1=57578063de1c591d559ffa487d599771662318a4beb66efcf1559ffa29163c9a